Astrogen
Thursday, June 06, 2024
Company Presentation
CNS/Neurological
Company Presentation Theater 2
Astrogen was founded by a pediatric neurologist and develops treatments for neurological diseases based on small molecules. AST-001, the core pipeline, is a treatment for core symptoms of autism spectrum disorder that can be applied from age 2. AST-001 showed superior efficacy and safety in phase 2 clinical trials, and is currently in phase 3 clinical trials. Recently, it was designated as an orphan drug by the Korea MFDS. AST-003 has improved solubility, PK, and ease of administration compared to AST-001, and clinical trials are scheduled to be conducted in Australia and the US. Subsequent pipelines are indicated for various intractable neurological diseases ranging from Rett syndrome(AST-004) and ADHD(AST-031) to Parkinson's disease(AST-030) and glioblastoma(AST-035). Among them, AST-035 is a thalidomide-based molecular glue and has superior efficacy, safety, stability, PK, and BBB permeability compared to reference drugs. Astrogen plans to establish a US corporation this year.
.jpg)
Company Website:
http://www.astrogen.co.kr
Lead Product in Development:
AST-001, a treatment for core symptoms of autism spectrum disorder
Number Of Unlicensed Products (For Which You Are Seeking Partners):
5 products: (1) Autism spectrum disorder (AST-003, an improved version of AST-001), (2) Rett syndrome (AST-004), (3) ADHD (AST-031), (4) Parkinson's disease (AST-030) and (5) Glioblastoma (AST-035). AST-030 has the advantage of being expandable to idiopathic pulmonary fibrosis (IPF) and AST-031 to obstructive sleep apnea (OSA), both of which have significant unmet clinical needs.
Company HQ City
Daegu
Company HQ State
Gyeongsangbuk-do
Company HQ Country
Korea, Republic of
CEO/Top Company Official
Su-Kyeong Hwang
Development Phase of Primary Product
Phase III
Primary Speaker
)
)
)
)
)
)
){kind=logo}
){kind=logo}
.png/fit-in/500x500/filters:no_upscale())